Pye, R and Darby, J and Flies, A and Fox, S and Carver, S and Elmer, J and Swift, K and Hogg, C and Pemberton, D and Woods, G and Lyons, AB, Post release immune responses of Tasmanian devils vaccinated with an experimental devil facial tumour disease vaccine, Wildlife Research ISSN 1035-3712 (2021) [Refereed Article]
|PDF (pre-print version)|
© CSIRO 2021. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) https://creativecommons.org/licenses/by-nc-nd/4.0/
Official URL: https://www.publish.csiro.au/WR/justaccepted/WR202...
Context: Disease is increasingly becoming a driver of wildlife population declines and extinction risk. Vaccines are one of the most successful health interventions in human history, but few have been tested for mitigating wildlife disease. The transmissible cancer, devil facial tumour disease (DFTD), triggered the Tasmanian devil’s (Sarcophilus harrisii) inclusion on the international endangered species list. In 2016, 33 devils from a DFTD-free insurance population were given an experimental DFTD vaccination prior to their wild release on the Tasmanian north coast.
Aim: To determine the efficacy of the vaccination protocol and the longevity of the induced responses.
Method: Six trapping trips took place over the 2.5 years following release, and both vaccinated and incumbent devils had blood samples and tumour biopsies collected.
Key results: Eight of the 33 vaccinated devils were re-trapped, and six of those developed DFTD within the monitoring period. Despite the lack of protection provided by the vaccine, we observed signs of immune activation not usually found in unvaccinated devils. Firstly, sera collected from the eight devils showed that anti-DFTD antibodies persisted for up to two years post vaccination. Secondly, tumour infiltrating lymphocytes were found in three out of four biopsies collected from vaccinated devils which contrasts with the ‘immune deserts’ typical of DFT’s; only one of the twenty incumbent devils with DFTD had a tumour biopsy exhibiting immune cell infiltrate. Thirdly, immunohistochemical analysis of the vaccinated devils’ tumour biopsies identified the functional immune molecules associated with antigen presenting cells (MHC-II) and T cells (CD3), and the immune checkpoint molecule PD-1, all associated with anti-tumour immunity in other species.
Conclusions: These results correlate with our previous study on captive devils in which a prophylactic vaccine primed the devil immune system and, following DFTD challenge and tumour growth, immunotherapy induced complete tumour regressions. The field trial results presented here provide further evidence that the devil immune system can be primed to recognise DFTD cells, but additional immune manipulation could be needed for complete protection or induction of tumour regressions.
Implications: A protective DFTD vaccine would provide a valuable management approach for conservation of the Tasmanian devil.
|Item Type:||Refereed Article|
|Keywords:||transmissible cancer, devil facial tumor, allograft, MHC-I, immune evasion, immune checkpoint, vaccine, trial|
|Research Division:||Agricultural, Veterinary and Food Sciences|
|Research Group:||Veterinary sciences|
|Research Field:||Veterinary immunology|
|Objective Division:||Expanding Knowledge|
|Objective Group:||Expanding knowledge|
|Objective Field:||Expanding knowledge in the biological sciences|
|UTAS Author:||Pye, R (Ms Ruth Pye)|
|UTAS Author:||Darby, J (Ms Jocelyn Darby)|
|UTAS Author:||Flies, A (Dr Andy Flies)|
|UTAS Author:||Carver, S (Dr Scott Carver)|
|UTAS Author:||Woods, G (Professor Gregory Woods)|
|UTAS Author:||Lyons, AB (Associate Professor Bruce Lyons)|
|Funding Support:||Australian Research Council (DE180100484)|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page